PE20191500A1 - Moduladores del receptor de estrogeno - Google Patents
Moduladores del receptor de estrogenoInfo
- Publication number
- PE20191500A1 PE20191500A1 PE2019001434A PE2019001434A PE20191500A1 PE 20191500 A1 PE20191500 A1 PE 20191500A1 PE 2019001434 A PE2019001434 A PE 2019001434A PE 2019001434 A PE2019001434 A PE 2019001434A PE 20191500 A1 PE20191500 A1 PE 20191500A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- ch2f
- estrogen receptor
- compounds
- fluorooxetan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451971P | 2017-01-30 | 2017-01-30 | |
| US201762523695P | 2017-06-22 | 2017-06-22 | |
| US201762560304P | 2017-09-19 | 2017-09-19 | |
| US201762592485P | 2017-11-30 | 2017-11-30 | |
| PCT/EP2018/052040 WO2018138303A1 (en) | 2017-01-30 | 2018-01-29 | Estrogen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191500A1 true PE20191500A1 (es) | 2019-10-22 |
Family
ID=61223883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001434A PE20191500A1 (es) | 2017-01-30 | 2018-01-29 | Moduladores del receptor de estrogeno |
Country Status (36)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3411034T3 (da) | 2016-02-05 | 2021-01-11 | Inventisbio Inc | Selektiv østrogenreceptornedbrydere og anvendelser deraf |
| DK3555097T3 (da) | 2016-12-16 | 2022-07-25 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| WO2021055749A1 (en) * | 2019-09-19 | 2021-03-25 | Totus Medicines Inc. | Therapeutic conjugates |
| MX2023010642A (es) | 2021-03-11 | 2023-11-28 | Janssen Pharmaceutica Nv | Lorpucitinib para uso en el tratamiento de trastornos mediados por jak. |
| CN115557920B (zh) * | 2022-09-22 | 2024-02-20 | 吉林奥来德光电材料股份有限公司 | 一种发光辅助材料、其制备方法及有机电致发光器件 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EE05405B1 (et) | 2000-08-10 | 2011-04-15 | Pharmacia Italia S.P.A. | Kinaasi inhibiitoritena toimivad bitskloprasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid |
| WO2005111208A1 (ja) * | 2004-04-27 | 2005-11-24 | Chugai Seiyaku Kabushiki Kaisha | プラズマ細胞の増殖方法 |
| EP1863810A4 (en) | 2005-03-22 | 2010-03-31 | Astrazeneca Ab | NEW TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLDERIVATE AS CB1 'RECEPTOR LIGANDS |
| FR2884252B1 (fr) | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
| AR058223A1 (es) | 2005-11-25 | 2008-01-23 | Palau Pharma Sa | Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto |
| JP2010505961A (ja) | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| WO2010138659A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating brain tumors |
| WO2010138695A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| EP2434891B9 (en) | 2009-05-27 | 2021-05-05 | PTC Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
| DK2580210T5 (en) | 2010-06-10 | 2017-06-19 | Seragon Pharmaceuticals Inc | ESTROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF |
| WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| EP2791133B1 (en) | 2011-12-14 | 2019-04-17 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
| PE20160874A1 (es) * | 2013-05-28 | 2016-09-04 | Astrazeneca Ab | Compuestos quimicos |
| CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| PE20171330A1 (es) * | 2014-12-18 | 2017-09-13 | Hoffmann La Roche | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos |
| JP6807841B2 (ja) | 2014-12-18 | 2021-01-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーター及びその使用 |
| US20160175284A1 (en) | 2014-12-18 | 2016-06-23 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| CN107531722B (zh) | 2015-05-26 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 杂环雌激素受体调节剂及其用途 |
| AU2016279330B2 (en) | 2015-06-16 | 2020-05-14 | Jiangsu Hengrui Medicine Co., Ltd. | Piperidine derivative and preparation method and pharmaceutical use thereof |
| CN106518768B (zh) | 2015-09-15 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的应用 |
| EP3355884B1 (en) | 2015-10-01 | 2021-04-28 | Olema Pharmaceuticals, Inc. | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS |
| JP6920295B2 (ja) | 2015-11-09 | 2021-08-18 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用 |
| CA3011391C (en) | 2015-11-12 | 2021-02-09 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| MX2018007844A (es) | 2015-12-22 | 2019-01-21 | Jiangsu Hengrui Medicine Co | Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo. |
| JP7241542B2 (ja) | 2016-04-08 | 2023-03-17 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | テトラヒドロイソキノリン エストロゲン受容体モジュレーター及びその使用 |
| WO2017182493A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer |
| CN109415388A (zh) | 2016-05-06 | 2019-03-01 | 路易斯安那泽维尔大学 | 选择性雌激素受体下调剂(serds) |
| WO2018001232A1 (zh) | 2016-06-29 | 2018-01-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
| US10149839B2 (en) * | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| CN107814798B (zh) | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| ES2975558T3 (es) | 2016-09-15 | 2024-07-09 | Arvinas Inc | Derivados de indol como degradantes de receptor de estrógeno |
| BR102016024814A2 (pt) | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| AU2017349797B2 (en) | 2016-10-24 | 2020-05-21 | Astrazeneca Ab | 6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| WO2018108671A1 (en) | 2016-12-16 | 2018-06-21 | Basf Se | Pesticidal compounds |
| TN2019000158A1 (en) | 2016-12-16 | 2020-10-05 | Lilly Co Eli | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
| EA037318B1 (ru) | 2016-12-16 | 2021-03-11 | Пфайзер Инк. | Агонисты рецептора glp-1 и их применение |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| DK3555097T3 (da) | 2016-12-16 | 2022-07-25 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| WO2018138293A1 (en) | 2017-01-30 | 2018-08-02 | Chiesi Farmaceutici S.P.A. | Tyrosine amide derivatives as rho- kinase inhibitors |
-
2018
- 2018-01-29 UA UAA201909412A patent/UA125043C2/uk unknown
- 2018-01-29 AU AU2018211495A patent/AU2018211495B2/en active Active
- 2018-01-29 PE PE2019001434A patent/PE20191500A1/es unknown
- 2018-01-29 JP JP2019538615A patent/JP6951451B2/ja active Active
- 2018-01-29 MY MYPI2019004298A patent/MY196317A/en unknown
- 2018-01-29 HU HUE18705097A patent/HUE047761T2/hu unknown
- 2018-01-29 CN CN201880008715.8A patent/CN110214140B/zh active Active
- 2018-01-29 CR CR20190379A patent/CR20190379A/es unknown
- 2018-01-29 KR KR1020197025253A patent/KR102246668B1/ko active Active
- 2018-01-29 MX MX2019008438A patent/MX2019008438A/es unknown
- 2018-01-29 TN TNP/2020/000009A patent/TN2020000009A1/en unknown
- 2018-01-29 WO PCT/EP2018/052040 patent/WO2018138303A1/en not_active Ceased
- 2018-01-29 EP EP19203383.5A patent/EP3689873B1/en active Active
- 2018-01-29 MA MA052555A patent/MA52555A/fr unknown
- 2018-01-29 ES ES19203383T patent/ES2931320T3/es active Active
- 2018-01-29 SM SM20200010T patent/SMT202000010T1/it unknown
- 2018-01-29 SG SG11201906767XA patent/SG11201906767XA/en unknown
- 2018-01-29 US US15/881,962 patent/US10221173B2/en active Active
- 2018-01-29 JO JOP/2019/0183A patent/JOP20190183B1/ar active
- 2018-01-29 SI SI201830022T patent/SI3494116T1/sl unknown
- 2018-01-29 DK DK18705097.6T patent/DK3494116T3/da active
- 2018-01-29 PL PL18705097T patent/PL3494116T3/pl unknown
- 2018-01-29 PT PT187050976T patent/PT3494116T/pt unknown
- 2018-01-29 LT LTEP18705097.6T patent/LT3494116T/lt unknown
- 2018-01-29 RS RS20200018A patent/RS59770B1/sr unknown
- 2018-01-29 CA CA3050337A patent/CA3050337A1/en active Pending
- 2018-01-29 EP EP18705097.6A patent/EP3494116B1/en active Active
- 2018-01-29 TW TW107103088A patent/TWI794205B/zh active
- 2018-01-29 ES ES18705097T patent/ES2766249T3/es active Active
-
2019
- 2019-01-31 US US16/263,683 patent/US10590132B2/en active Active
- 2019-07-15 CL CL2019001991A patent/CL2019001991A1/es unknown
- 2019-07-16 DO DO2019000183A patent/DOP2019000183A/es unknown
- 2019-07-17 ZA ZA2019/04696A patent/ZA201904696B/en unknown
- 2019-07-25 IL IL268263A patent/IL268263B/en unknown
- 2019-07-26 NI NI201900080A patent/NI201900080A/es unknown
- 2019-07-26 PH PH12019501724A patent/PH12019501724A1/en unknown
- 2019-08-16 CO CONC2019/0008941A patent/CO2019008941A2/es unknown
- 2019-08-28 EC ECSENADI201962381A patent/ECSP19062381A/es unknown
-
2020
- 2020-01-08 CY CY20201100014T patent/CY1122731T1/el unknown
- 2020-01-29 US US16/775,781 patent/US11046689B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191500A1 (es) | Moduladores del receptor de estrogeno | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| PE20191495A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| EA201400125A1 (ru) | Фунгицидные замещенные 2-[2-галогеналкил-4-(фенокси)фенил]-1-[1,2,4]триазол-1-ил-этанольные соединения | |
| EA201400230A1 (ru) | Фунгицидные замещенные 1-{2-[2-галоген-4-(4-галогенфенокси)фенил]-2-этоксиэтил}-1н-[1,2,4]триазольные соединения | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| CY1122610T1 (el) | Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| MA34604B1 (fr) | Derives de la pyrazine en tant que bloqueurs de l'enac | |
| GEP20166472B (en) | Androgen receptor modulating compounds | |
| EA201590200A1 (ru) | Модуляторы пути активации комплемента и их применение | |
| EA201490320A1 (ru) | Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a | |
| JP2015516420A5 (enExample) | ||
| CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
| AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
| PE20140604A1 (es) | Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa | |
| RU2014149183A (ru) | Проницаемые ингибиторы гликозидазы и их применения | |
| MA37929B1 (fr) | Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch | |
| EA201400878A1 (ru) | Паразитицидные пероральные ветеринарные композиции, включающие системно действующие активные агенты, способы и применение этих композиций и способов | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| CL2011003302A1 (es) | Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros. | |
| TR201902057T4 (tr) | Tetrasiklin bileşikleri. |